Aspen Pharmacare normalised earnings rise 22%, HEPS to 801.5 cents
Aspen Pharmacare reported a 22% rise in normalised earnings, with normalised headline HEPS increasing to 801.5 cents. Growth was supported by strong momentum in its commercial pharmaceuticals unit during the reporting period.
South Africa's Aspen Pharmacare JSE:APN reported on Wednesday a 22% rise in normalised earnings, supported by strong momentum in its commercial pharmaceuticals unit, which was the main driver of growth in the reporting period.Normalised headline earnings per share (HEPS) rose to 801.5 cents in the…